Share on

Asia Pacific Overactive Bladder Treatment Market Research Report - Segmented By Treatment, Disease & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2023 to 2028)

Published: March, 2023
ID: 7586
Pages: 145
Formats: report pdf report excel report power bi report ppt

APAC Overactive Bladder Treatment Market Size & Growth (2023 to 2028):

As per the research report, the size of the Asia Pacific Overactive Bladder Treatment Market is valued at USD 0.80 billion in 2023 and is projected to grow at a CAGR of 2.98%, to reach USD 0.93 billion by 2028 during the forecast period 2023 to 2028.

The rising prevalence of overactive bladder cases across the Asia-Pacific region primarily drives the growth of the APAC overactive bladder treatment market. Approximately 10% of the population in India is affected by overactive bladder, ranging from mild to severe. Overactive bladder is characterized by uncontrollable urges to urinate, occurring frequently throughout the day and night. Factors contributing to overactive bladder include nerve damage, infection, abdominal trauma, excess weight, alcohol consumption and certain medications. The condition is more prevalent among men compared to women. Overactive bladder can lead to emotional distress, anxiety, sleep disturbances, and issues with sexual life. Urinary leakage often occurs during actions such as coughing, sneezing, exercising, or laughing. Healthcare providers recommend diagnostic procedures to reduce the severity of overactive bladder and alleviate associated symptoms.

The growing geriatric population and the rising incidence of neurological disorders across the APAC region further drive the growth of the overactive bladder treatment market in the Asia-Pacific region. The aging population is more susceptible to developing an overactive bladder, as age-related factors contribute to its occurrence. The older population is also at higher risk of chronic diseases, enlarged prostate, and diabetes, which can be underlying causes of overactive bladder in this demographic. Additionally, neurological disorders, including Alzheimer's disease, are known to contribute to overactive bladder issues. These factors contribute to the market growth as the demand for effective treatments for overactive bladder increases due to the aging population and the prevalence of associated neurological conditions.

The growing research and development efforts and increasing number of advancements in treatment procedures contributes to the growth of the overactive bladder treatment market in the APAC region. Researchers are dedicated to developing various types of surgeries and treatment processes aimed at preventing or reducing overactive bladder issues. The support of healthcare organizations, the presence of key players and an increasing number of mergers within the industry further fuels the growth rate of the APAC market.

The high cost of surgical procedures is one of the major factors hampering the growth of the overactive bladder treatment market. Factors such as the shortage of skilled professionals, lack of awareness, product recalls, social stigma, lengthy product approval processes and inadequate reimbursement policies further hinder the regional market growth. The potential side effects associated with overactive bladder drugs, including heartburn, constipation, blurry vision, skin issues and rapid heartbeat showcases negative impact on the APAC market growth.

This research report on the APAC Overactive Bladder Treatment Market has been segmented and sub-segmented into the following categories:

By Treatment:

  • Mirabegron
  • Anticholinergics
  • Botox
  • Intravesical Instillation
  • Neurostimulation

By Disease:

  • Neurogenic Overactive Bladder
  • Idiopathic Overactive Bladder

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Asia Pacific region accounts for a substantial share of the worldwide market during the forecast period. Factors such as increasing awareness of overactive bladder, rising cases among children, favorable reimbursement policies and increased healthcare expenditure drive the APAC market growth.

China and India accounted for the major share of the APAC market in 2022. The growing number of manufacturing facilities and pharmaceutical companies drives the market growth in these countries. Acupuncture is widely utilized for overactive bladder treatment in China, while researchers in the region focus on developing herbal-based drugs to minimize side effects. The approval of new treatments and the introduction of novel drugs by healthcare organizations also propel market growth in these countries.

Japan is predicted to account for a considerable share of the APAC market during the forecast period and is primarily driven by the presence of research laboratories and an increasing number of clinical trial centers. The availability of overactive bladder drugs in both offline and online stores further stimulates market demand in Japan.

The Top Companies in the APAC Overactive Bladder Treatment Market profiled in the report are Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V, Sanofi, Aurobindo Pharma Ltd, and Endo International.,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample